shutterstock_1349460611_pavel_kapysh
Pavel Kapysh / Shutterstock.com
23 December 2019AmericasSarah Morgan

Bausch Health resolves patent litigation with Glenmark

Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali (halobetasol propionate) lotion.

As part of the settlement, Bausch will grant Glenmark a non-exclusive US licence, effective 2026, to the IP relating to Bryhali lotion.

The lotion, which is used to treat plaque psoriasis in adults, is manufactured by Bausch’s dermatology unit Ortho Dermatologics.

Bausch sued Glenmark in June this year, at the US District Court for the District of New Jersey, after Glenmark filed an Abbreviated New Drug Application (ANDA) for a generic version of Bryhali.

Beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali lotion, if it receives approval from the US Food and Drug Administration on its ANDA.

Bausch and Glenmark have agreed to dismiss all litigation relating to the lotion.

US patent number 8,809,307, the final patent on the lotion, expires in 2031, according to a press release from Bausch, published on Friday, December 20.

Bausch said: “Bausch Health remains confident in the strength of the Bryhali lotion patents, and we will continue to vigorously defend its IP.”

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).

More on this story

Americas
2 August 2019   Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Americas
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).